AcelRx Pharmaceuticals Inc ACRX shares leaped 11% to $3.64, after the company disclosed that its investigational product candidate ARX-04 provided solid tolerance level in an open-label Phase three trial for post operative acute pain treatment. Share volume totaled 2.9 million, compared to an all-day average of 350,000
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
